FDA Approves First-ever RSV Vaccine
The shots will be available for older adults
The Food and Drug Administration (FDA) approved Wednesday the first-ever vaccine to combat severe respiratory syncytial virus, or RSV.
Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 and older and was 82 percent effective at preventing lower respiratory tract illness caused by RSV, according to trial data. It was also 94 percent effective in those who had at least one underlying medical condition.
“Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States," said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.
Please select this link to read the complete article from USA Today.